healthcare

Why Eiger BioPharma Shares Are Getting Crushed

Shares of Eiger BioPharmaceuticals Inc. (NASDAQ: EIGR) cratered on Tuesday after the firm announced that its midstage study in pulmonary arterial hypertension (PAH) did not meet its primary endpoint. As ...
Read Full Story »

Merck Wins Big With Late-Stage Lung Cancer Drug Results

Shares of Merck & Co. Inc. (NYSE: MRK) saw a handy gain on Tuesday after the pharma giant reported that its late-stage trial of Keytruda met its dual primary endpoints ...
Read Full Story »

Solid Biosciences Announces Potential Pricing for IPO

Solid Biosciences has filed an amended S-1 form with the U.S. Securities Exchange Commission (SEC) regarding its initial public offering (IPO). The company intends to price its 5.89 million shares ...
Read Full Story »

Meet the Top Biotech Movers of This Past Week

Over the past week, a few biotech companies made absolutely massive runs, while others fell off a cliff. Although health care only kept pace with the broader markets in 2017, ...
Read Full Story »

Menlo Therapeutics Announces Potential Pricing for IPO

Menlo Therapeutics has filed an amended S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). The company expects to price its 5.67 million ...
Read Full Story »

Short Sellers Grow More Selective on Major Biotechs

The short interest data are out for the most recent settlement date, December 29. Generally speaking, companies within the biotech industry are considered to be a riskier group of stocks, ...
Read Full Story »

Major Pharma Short Interest Takes a Plunge

Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study ...
Read Full Story »

Why Alder Biopharma Is Winning Big on Monday

Alder Biopharmaceuticals Inc. (NASDAQ: ALDR) saw its shares make a solid gain on Monday amid a blizzard of updates from the company. Overall, the firm met its primary endpoint in ...
Read Full Story »

Axovant Crumbles Following Alzheimer’s Study Update

Axovant Sciences Ltd. (NASDAQ: AXON) watched its shares practically get halved in Monday’s session after the firm provided an update from a few of its midstage clinical trials. While one ...
Read Full Story »

20 More Biopharma Catalysts Coming in 2018

Over the course of 2017, biopharmaceutical companies more or less kept pace with the markets, ending up with a return just a little higher than the S&P 500. But going in ...
Read Full Story »

Investors Cheer Secondary Offering for Gene-Editing Firm

CRISPR Therapeutics A.G. (NASDAQ: CRSP) saw its shares make a handy gain to close out the week after the firm announced that it would be pricing its secondary offering. While ...
Read Full Story »

Meet Merrill Lynch’s Top Biotech Picks for 2018

While 2017 was a strong year for the markets — especially technology stocks — biotech and health care stocks in general were only able to keep pace. The iShares Nasdaq ...
Read Full Story »

US AG Sessions Wants to Enforce Federal Prohibition of Marijuana

The Associated Press reported Thursday morning that sources told the AP that U.S. Attorney General Jeff Sessions will rescind the Obama-era policy not enforcing federal laws prohibiting the sale, possession ...
Read Full Story »

Audentes Therapeutics Pulls Off Positive Interim Results

Audentes Therapeutics Inc. (NASDAQ: BOLD) shares made a handy gain on Thursday after the company announced positive interim data for its midstage trial in patients with X-linked myotubular myopathy (XLMTM). ...
Read Full Story »

2018 Bull/Bear Outlook Pfizer and Merck: Where Does Major Health Care Go From Here?

Now that 2017 has come and gone, this raging bull market is now nearing nine years old. It is also the strongest bull market that most investors have seen in ...
Read Full Story »